Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapyImpact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R